3rd generation glp 1 agonist GLP-1 Agonists - What is it? Schematic illustration of monoagonists, dual
Description
Landmark clinical trials, such as the STEP programme for semaglutide published in The New England Journal of Medicine, have demonstrated that these medications can lead to average weight loss of 15% or more when combined with lifestyle changes, a level of efficacy previously achievable only through bariatric surgery
Lilly Investors
A systematic review pooling data from 27,617 patients found that semaglutide use lowered MACE risk by 19% overall (RR 0.81)
Wing RR, Lang W, Wadden TA, et al
G., & Ramasamy, A
